Targeting Plasmodium PI(4)K to eliminate malaria

Nature

Volumn 504, Issue 7479, 2013, Pages 248-253

  McNamara, Case W ^a   Lee, Marcus C S ^b   Lim, Chek Shik ^c   Lim, Siau Hoi ^c   Roland, Jason ^a   Nagle, Advait ^a   Simon, Oliver ^c   Yeung, Bryan K S ^c   Chatterjee, Arnab K ^a   McCormack, Susan L ^a   Manary, Micah J ^d   Zeeman, Anne Marie ^e   Dechering, Koen J ^f   Kumar, T R Santha ^b   Henrich, Philipp P ^b   Gagaring, Kerstin ^a   Ibanez, Maureen ^a   Kato, Nobutaka ^a   Kuhen, Kelli L ^a   Fischli, Christoph ^g   Rottmann, Matthias ^g,h   Plouffe, David M ^a   Bursulaya, Badry ^a   Meister, Stephan ^d   Rameh, Lucia ⁱ   Trappe, Joerg ^j   Haasen, Dorothea ^j   Timmerman, Martijn ^f   Sauerwein, Robert W ^f,k   Suwanarusk, Rossarin ^l   Russell, Bruce ^l,m   Renia, Laurent ^l   Nosten, Francois ^n,o   Tully, David C ^a   Kocken, Clemens H M ^e   Glynne, Richard J ^a   Bodenreider, Christophe ^c   Fidock, David A ^b   Diagana, Thierry T ^c   Winzeler, Elizabeth A ^a,d   more..

^a GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION   (United States)

^b Department of Medicine   (United States)

^c Novartis Institutes for Tropical Disease   (Singapore)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^e BIOMEDICAL PRIMATE RESEARCH CENTRE   (Netherlands)

^f Current affiliation: TropIQ Health Sciences   (Netherlands)

^g SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^h UNIVERSITY OF BASEL   (Switzerland)

ⁱ BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j NOVARTIS PHARMA AG   (Switzerland)

^k RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^l AGENCY FOR SCIENCE   (Singapore)

^m NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

ⁿ UNIVERSITY OF OXFORD   (United Kingdom)

^o MAHIDOL UNIVERSITY   (Thailand)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; BQR 695; DIHYDROARTEMISININ; IMIDAZOPYRAZINE DERIVATIVE; KAI 407; KAI 715; KDU 691; PHOSPHATIDYLINOSITOL 4 PHOSPHATE; PHOSPHATIDYLINOSITOL KINASE; QUINOXALINE; UNCLASSIFIED DRUG;

ANTIMALARIAL AGENT; BIOCHEMISTRY; DISEASE CONTROL; DISEASE TREATMENT; ENZYME ACTIVITY; INHIBITOR; LIPID; MALARIA; MEDICINE; PARASITE; PATHOGEN; PROTOZOAN; RODENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC RESISTANCE; ANTIMALARIAL ACTIVITY; ARTICLE; BINDING AFFINITY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOKINESIS; DRUG TARGETING; FEMALE; IC 50; LIFE CYCLE; MALARIA; MALE; MOUSE; NONHUMAN; PLASMODIUM; PLASMODIUM BERGHEI INFECTION; PLASMODIUM CYNOMOLGI; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PRIORITY JOURNAL;

1-PHOSPHATIDYLINOSITOL 4-KINASE; ADENOSINE TRIPHOSPHATE; ANIMALS; BINDING SITES; CYTOKINESIS; DRUG RESISTANCE; FATTY ACIDS; FEMALE; HEPATOCYTES; HUMANS; IMIDAZOLES; LIFE CYCLE STAGES; MACACA MULATTA; MALARIA; MALE; MODELS, BIOLOGICAL; MODELS, MOLECULAR; PHOSPHATIDYLINOSITOL PHOSPHATES; PLASMODIUM; PYRAZOLES; QUINOXALINES; RAB GTP-BINDING PROTEINS; REPRODUCIBILITY OF RESULTS; SCHIZONTS;

PLASMODIUM CYNOMOLGI; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; RODENTIA; SIMIAE; VERTEBRATA;

EID: 84890428942     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature12782     Document Type: Article

References (46)

1. Greenwood, B. M. et al. Malaria: progress, perils, and prospects for eradication. J. Clin. Invest. 118, 1266-1276 (2008)
2. Vale, N., Moreira, R. & Gomes, P. Primaquine revisited six decades after its discovery. Eur. J. Med. Chem. 44, 937-953 (2009)
3. Wells, T. N., Burrows, J. N. & Baird, J. K. Targeting the hypnozoite reservoir of Plasmodium vivax: the hidden obstacle to malaria elimination. Trends Parasitol. 26, 145-151 (2010)
4. Plouffe, D. et al. In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen. Proc. Natl Acad. Sci. USA 105, 9059-9064 (2008)
5. Dembele, L. et al. Towards an in vitromodel of Plasmodiumhypnozoites suitable for drug discovery. PLoS ONE 6, e18162 (2011)
6. Bousema, T. & Drakeley, C. Epidemiology and infectivity of Plasmodium falciparum and Plasmodium vivax gametocytes in relation to malaria control and elimination. Clin. Microbiol. Rev. 24, 377-410 (2011)
7. Adjalley, S. H. et al. Quantitative assessment of Plasmodium falciparum sexual development reveals potent transmission-blocking activity by methylene blue. Proc. Natl Acad. Sci. USA 108, E1214-E1223 (2011)
8. van Pelt-Koops, J. C. et al. The spiroindolone drug candidate NITD609 potently inhibits gametocytogenesis and blocks Plasmodium falciparum transmission to Anopheles mosquito vector. Antimicrob. Agents Chemother. 56, 3544-3548 (2012)
9. Boyle, M. J. et al. Isolation of viable Plasmodium falciparum merozoites to define erythrocyte invasion events and advance vaccine and drug development. Proc. Natl Acad. Sci. USA 107, 14378-14383 (2010)
10. Dvorin, J. D. et al. A plant-like kinase in Plasmodium falciparum regulates parasite egress from erythrocytes. Science 328, 910-912 (2010)
11. Drew, M. E. et al. Plasmodiumfood vacuole plasmepsins are activated by falcipains. J. Biol. Chem. 283, 12870-12876 (2008)
12. Rottmann, M. et al. Spiroindolones, a potent compound class for the treatment of malaria. Science 329, 1175-1180 (2010)
13. Dharia, N. V. et al. Use of high-density tiling microarrays to identify mutations globally and elucidate mechanisms of drug resistance in Plasmodium falciparum. Genome Biol. 10, R21 (2009)
14. Balla, A. & Balla, T. Phosphatidylinositol 4-kinases: old enzymes with emerging functions. Trends Cell Biol. 16, 351-361 (2006)
15. Mayinger, P. Phosphoinositides and vesicular membrane traffic. Biochim. Biophys. Acta 1821, 1104-1113 (2012)
16. Polevoy, G. et al. Dual roles for the Drosophila PI 4-kinase four wheel drive in localizing Rab11 during cytokinesis. J. Cell Biol. 187, 847-858 (2009)
17. Straimer, J. et al. Site-specific genome editing in Plasmodium falciparum using engineered zinc-finger nucleases. Nature Methods 9, 993-998 (2012)
18. Nkrumah, L. J. et al. Efficient site-specific integration in Plasmodium falciparum chromosomes mediated by mycobacteriophage Bxb1 integrase. Nature Methods 3, 615-621 (2006)
19. Agop-Nersesian, C. et al. Rab11A-controlled assembly of the inner membrane complex is required for completion of apicomplexan cytokinesis. PLoS Pathog. 5, e1000270 (2009)
20. Noble, M. E. M., Endicott, J. A. & Johnson, L. N. Protein kinase inhibitors: insights into drug design from structure. Science 303, 1800-1805 (2004)
21. Roy, A. & Levine, T. P. Multiple pools of phosphatidylinositol 4-phosphate detected using the pleckstrin homology domain of Osh2p. J. Biol. Chem. 279, 44683-44689 (2004)
22. Krüger, T., Sanchez, C. P. & Lanzer, M. Complementation of Saccharomyces cerevisiae pik1ts by a phosphatidylinositol 4-kinase from Plasmodium falciparum. Mol. Biochem. Parasitol. 172, 149-151 (2010)
23. Strahl, T., Hama, H., DeWald, D. B. & Thorner, J. Yeast phosphatidylinositol 4-kinase, Pik1, has essential roles at the Golgi and in the nucleus. J. Cell Biol. 171, 967-979 (2005)
24. Walch-Solimena, C. & Novick, P. The yeast phosphatidylinositol-4-OH kinase Pik1 regulates secretion at the Golgi. Nature Cell Biol. 1, 523-525 (1999)
25. Hama, H., Schnieders, E. A., Thorner, J., Takemoto, J. Y. & DeWald, D. B. Direct involvement of phosphatidylinositol 4-phosphate in secretion in the yeast Saccharomyces cerevisiae. J. Biol. Chem. 274, 34294-34300 (1999)
26. de Graaf, P. et al. Phosphatidylinositol 4-kinaseb is critical for functional associationofRab11with theGolgi complex. Mol. Biol. Cell15,2038-2047(2004)
27. LaMarche, M. J. et al. Anti-hepatitis C virus activity and toxicity of type III phosphatidylinositol-4-kinase beta inhibitors. Antimicrob. Agents Chemother. 56, 5149-5156 (2012)
28. The malERA Consultative Group on Drugs. A research agenda for malaria eradication: drugs. PLoS Med. 8, e1000402 (2011)
29. Meister, S. et al. Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery. Science 334, 1372-1377 (2011)
30. Russell, B. et al. Determinants of in vitro drug susceptibility testing of Plasmodium vivax. Antimicrob. Agents Chemother. 52, 1040-1045 (2008)
31. Russell, B. M. et al. Simple in vitro assay for determining the sensitivity of Plasmodium vivax isolates from fresh human blood to antimalarials in areas where P. vivax is endemic. Antimicrob. Agents Chemother. 47, 170-173 (2003)
32. D'Alessandro, S. et al. A Plasmodium falciparum screening assay for anti-gametocyte drugs based on parasite lactate dehydrogenase detection. J. Antimicrob. Chemother. 68, 2048-2058 (2013)
33. Dechering, K. J., Thompson, J., Dodemont, H. J., Eling, W. & Konings, R. N. Developmentally regulated expression of pfs16, amarker for sexual differentiation of the humanmalaria parasite Plasmodium falciparum. Mol. Biochem. Parasitol. 89, 235-244 (1997)
34. van der Kolk, M. et al. Evaluation of the standard membrane feeding assay (SMFA) for the determination of malaria transmission-reducing activity using empirical data. Parasitology 130, 13-22 (2005)
35. Janse, C. J., Ramesar, J. & Waters, A. P. High-efficiency transfection and drug selection of genetically transformed blood stages of the rodent malaria parasite Plasmodium berghei. Nature Protocols 1, 346-356 (2006)
36. Li, C. et al. Amodernin vivopharmacokineticparadigm: combining snapshot, rapid andfullPKapproaches to optimize and expedite early drug discovery. Drug Discov. Today 18, 71-78 (2013)
37. Ponnudurai, T. et al. Infectivity of cultured Plasmodium falciparum gametocytes to mosquitoes. Parasitology 98, 165-173 (1989)
38. Guguen-Guillouzo, C. et al. High yield preparation of isolated human adult hepatocytes by enzymatic perfusion of the liver. Cell Biol. Int. Rep. 6, 625-628 (1982)
39. Mazier, D. et al. Complete development of hepatic stages of Plasmodium falciparum in vitro. Science 227, 440-442 (1985)
40. Fidock, D. A., Nomura, T. & Wellems, T. E. Cycloguanil and its parent compound proguanil demonstrate distinct activities against Plasmodium falciparum malaria parasites transformed with human dihydrofolate reductase. Mol. Pharmacol. 54, 1140-1147 (1998)
41. Franke-Fayard, B. et al. A Plasmodium berghei reference line that constitutively expresses GFP at a high level throughout the complete life cycle. Mol. Biochem. Parasitol. 137, 23-33 (2004)
42. Doyon, Y. et al. Heritable targeted gene disruption in zebrafish using designed zinc-finger nucleases. Nature Biotechnol. 26, 702-708 (2008)
43. Furet, P. et al. Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation. Bioorg. Med. Chem. Lett. 23, 3741-3748 (2013)
44. Manley, P. W. et al. Extended kinase profile and properties of the protein kinase inhibitor nilotinib. Biochim. Biophys. Acta 1804, 445-453 (2010)
45. Onishi, M. et al. Role of septins in the orientation of forespore membrane extension during sporulation in fission yeast. Mol. Cell. Biol. 30, 2057-2074 (2010)
46. Mandl, A., Sarkes, D., Carricaburu, V., Jung, V. & Rameh, L. Serum withdrawal-induced accumulation of phosphoinositide 3-kinase lipids in differentiating 3T3-L6myoblasts: distinct roles for Ship2 and PTEN. Mol. Cell. Biol. 27, 8098-8112 (2007)